FHIR © HL7.org  |  Server Home  |  XIG Home  |  XIG Stats  |  Server Source  |  FHIR  

FHIR IG Statistics: FHIR Resources

Resources - Measure, Realm UV

125 resources

Type: Text:

By Version

By Authority

 

PackageVersionIdentityName/TitleStatusFMMWGDateAuth
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-1Bystander Chest Compressionsunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-10TBDunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-2Dispatch coached chest compressionsunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-3Time from PSAP to initial compressionsunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-4Time to initial shockunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-5Average chest compression rateunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-6Average chest compression depthunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-7Return of Spontaneous Circulation (ROSC)during EMS careunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-8Survival of OHCA with all presenting rhythmsunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-CPR-9Survival of OHCA when witnessed by bystanderunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Hypoglycemia-01Treatment Administered for Hypoglycemiaunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Hypoglycemia-02Improved Post-Treatment Conditionunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Hypoglycemia-03Hypoglycemic Patients Treated and not Transportedunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Hypoglycemia-04Repeat Response for Patient Previously Not Transportedunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-01Percentage of suspected opioid OD patients who received Narcanunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-02Percentage of suspected opioid OD patients transported to an EDunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-03Percentage of suspected opioid OD patients given multiple Narcan doses in case of an “Unchanged” response to the first doseunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-04Percentage of suspected opioid OD patients experiencing a repeat OD within a specified time period.unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-05Percentage of suspected opioid OD patients with a recorded combination of altered mental status, poor respiratory effort (RR<12 per minute), and pin point pupils.unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-06Percentage of suspected opioid OD patients with a specific opioid recordedunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-07Percentage of suspected opioid OD patients experiencing an Increase in pulse oximetry after EMS care.unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-08Percentage of suspected opioid OD patients experiencing an Increase in Glasgow Coma Scale (GCS) after EMS care.unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-09Percentage of suspected opioid OD patients experiencing an Increase in respiratory rate after EMS care.unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-10Percentage of suspected opioid OD patients who received ventilatory support within five minutes of first EMS unit’s arrival on scene.unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Opioid-11Percentage of suspected opioid OD patients experiencing who exhibit adverse effects after naloxone administrationunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-PEDS-01Respiratory Assessment - Pediatricunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-PEDS-02Administration of beta agonist for pediatric asthmaunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-PEDS-03Documentation of estimated weight in kilograms - pediatricunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-PEDS-04Medication error rateunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-STEMI-1Time to first EKGunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-STEMI-2Time to receiving facility pre-notificationunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-STEMI-3Transport to PCI/Thrombolytic capable facilitiesunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-STEMI-4Time from First medical contact to receiving facilityunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-STEMI-5Patients with complete bundle of careunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-STEMI-6EMS correctly identified STEMIunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-STEMI-7Time to Reperfusionunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-01Lights and Sirens Response to Scene Rateunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-02Lights and Sirens Transport Rateunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-03Number of crashesunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-04Number of crashes resulting in injuryunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-05Number of fatal crashesunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-06Rate of crashes per 100,000miunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-07Rate of crashes resulting in injury per 100,000miunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Safety-08Rate of fatalities per 100,000miunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Seizure-01Blood Glucose Evaluationunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Seizure-02Patient Received Interventionunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Seizure-03Patients with Terminated Seizuresunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-01Suspected Stroke Receiving Prehospital Stroke Assessmentunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-02Blood Glucose Measurement for Patients with a Provider Impression of Strokeunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-03Prehospital Notificationunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-04Positive Stroke Assessments Transported to a Hospital Verified, Designated or Otherwise Identified as Acute Stroke-Ready or Higherunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-05Provider Impression of Stroke with Last Known Well (LKW) Documented unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-06Prehospital Stroke Care Bundleunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-07For Patients with Positive Stroke Assessment, Average Time from Last Known Well to Arrival at a Hospital Verified, Designated or Otherwise Identified as Acute Stroke-Ready or Higherunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Stroke-08Emergency Department Diagnosed Stroke Identified by Prehospital Stroke Assessment unknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Trauma-01Pain assessment of injured patientsunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Trauma-02Pain re-assessment of injured patientsunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Trauma-03Effectiveness of pain management for injured patientsunknown2024-10ihe
ihe.qrph.qoreR4Measure/example-IHE-QORE-Trauma-04Trauma patients transported to trauma centerunknown2024-10ihe
ihe.palm.rpcR4Measure/MeasureBreastDistanceFromTheNippleBreast Distance from the Nipple Rad Path Correlationdraft2023-06ihe
ihe.palm.rpcR4Measure/MeasureBreastLateralityBreast Laterality Rad Path Correlationdraft2023-06ihe
ihe.palm.rpcR4Measure/MeasureBreastLocationOfLesionBreast Location of Lesion Rad Path Correlationdraft2023-06ihe
ihe.palm.rpcR4Measure/MeasureBreastQuadrantAndClockFaceBreast Quadrant and Clock Face Rad Path Correlationdraft2023-06ihe
ihe.palm.rpcR4Measure/MeasureGleasonGleason Score Rad Path Correlationdraft2023-06ihe
ihe.palm.rpcR4Measure/MeasureProstateLesionSizeProstate Lesion Size Rad Path Correlationdraft2023-06ihe
ihe.palm.rpcR4Measure/MeasureProstateSizeProstate Size Rad Path Correlationdraft2023-06ihe
ihe.palm.rpcR4Measure/MeasureProstateTumorLocationProstate Tumor Location Rad Path Correlationdraft2023-06ihe
hl7.fhir.uv.cqmR4Measure/measure-cqm-publishable-exampleMeasure CQM Publishable Exampleactive2025-07hl7
hl7.fhir.uv.cqmR4Measure/age-stratified-exampleMeasure Age Stratified Exampleactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/measure-pi-exmEXM Promoting Interoperability Measureactive2023-05hl7
hl7.fhir.uv.cqmR4Measure/EXMLogic-FHIREXM Measureactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/EXMRatio-FHIREXM Ratio Measureactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/measure-publishable-exmEXM Publishable Measureactivecqi2025-08hl7
hl7.fhir.uv.cpgR4Measure/chf-bodyweight-change-measureCHF Body Weight Change Metricactive2024-11hl7
hl7.fhir.uv.cpgR4Measure/chf-bodyweight-measureCHF Body Weight Metricactive2024-11hl7
example.fhir.uv.mycontentigR4Measure/HRExampleCVMeasureHR Example CV (Measure Name in Details Tab of MADiE UI)draft2025-08hl7
example.fhir.uv.mycontentigR4Measure/HRExampleCohortMeasureHR Example Cohort (Measure Name in Details Tab of MADiE UI)draft2025-08hl7
example.fhir.uv.mycontentigR4Measure/HRExampleProportionMeasureHR Example Proportion (Measure Name in Details Tab of MADiE UI)draft2025-08hl7
example.fhir.uv.mycontentigR4Measure/HRExampleRatioMeasureHR Example Ratio (Measure Name in Details Tab of MADiE UI)draft2025-08hl7
hl7.fhir.uv.cpgR4Measure/activity-example-generatereport-measureActivity Example Generate Report Measureactive2023-10hl7
example.fhir.uv.mycontentigR4Measure/QuestionnaireMeasureExampleQuestionnaire Measure Exampledraft2025-08hl7
ihe.qrph.madxR4Measure/madx-hiv-indicator-example1mADX-Measure-example1draft2024-08ihe
ihe.qrph.madxR4Measure/madx-hiv-indicator-example2mADX-Measure-example2draft2024-08ihe
example.fhir.uv.mycontentigR4Measure/DischargedonAntithromboticTherapyFHIRExampleDischarged on Antithrombotic Therapy FHIR Exampledraft2025-08hl7
hl7.fhir.uv.cqmR4Measure/EXM130-FHIREXM130 - Colorectal Cancer Screening Measureactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/EXM146-FHIREXM146 - Appropriate Testing for Children with Pharyngitisactive2025-08hl7
example.fhir.uv.mycontentigR4Measure/HIVViralSuppressionFHIRExampleHIV Viral Suppression FHIR Exampledraft2025-08hl7
smart.who.int.ancR4Measure/ANCIND12ANC.IND.12 Percentage of pregnant women counselled and tested for HIVdraft2025-06who
smart.who.int.ancR4Measure/ANCIND03ANC.IND.03 Percentage of pregnant women screened for syphilis during ANCdraft2025-06who
smart.who.int.ancR4Measure/ANCIND02ANC.IND.02 Percentage of pregnant women who received iron and folic acid (IFA) supplements for 90+ daysdraft2025-06who
smart.who.int.ancR4Measure/ANCIND13ANC.IND.13 Percentage of pregnant women who received oral pre-exposure prophylaxis (PrEP)draft2025-06who
smart.who.int.ancR4Measure/ANCIND05ANC.IND.05 Percentage of pregnant women with a minimum of eight antenatal care contactsdraft2025-06who
smart.who.int.ancR4Measure/ANCIND10ANC.IND.10 Percentage of pregnant women with an ultrasound scan before 24 weeksdraft2025-06who
smart.who.int.ancR4Measure/ANCIND04ANC.IND.04 Percentage of pregnant women with at least four ANC contactsdraft2025-06who
smart.who.int.ancR4Measure/ANCIND07ANC.IND.07 Percentage of pregnant women with at least one blood pressure measure during ANCdraft2025-06who
smart.who.int.ancR4Measure/ANCIND08ANC.IND.08 Percentage of pregnant women with at least one blood pressure measure in the third trimester during ANCdraft2025-06who
hl7.fhir.uv.crmiR4Measure/publishable-exampleANC.IND.01 Percentage of pregnant women with first ANC contact in the first trimester (Publishable Example)draft2023-03hl7
hl7.fhir.uv.crmiR4Measure/shareable-exampleANC.IND.01 Percentage of pregnant women with first ANC contact in the first trimester (Shareable Example)draft2023-03hl7
smart.who.int.ancR4Measure/ANCIND01ANC.IND.01 Percentage of pregnant women with first ANC contact in the first trimesterdraft2025-06who
hl7.fhir.uv.cqmR4Measure/EXM124-FHIREXM124 - Cervical Cancer Screeningactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/EXM125-FHIREXM125 - Breast Cancer Screeningactive2025-08hl7
smart.who.int.ancR4Measure/ANCIND11ANC.IND.11 Percentage of women who received three doses or more of intermittent preventive therapy for malaria (IPTp) during their last pregnancydraft2025-06who
smart.who.int.ancR4Measure/ANCIND09ANC.IND.09 Percentage of pregnant women whose baby’s heartbeat was listened to at least once during ANCdraft2025-06who
smart.who.int.ancR4Measure/ANCIND06ANC.IND.06 Pregnant women who received counselling on danger signs (%) during at least one ANC contactdraft2025-06who
hl7.fhir.uv.sanerR4Measure/CDCHealthcareSupplyPathwayCOVID-19 Healthcare Supply Pathwaydraft2020-04hl7
hl7.fhir.uv.sanerR4Measure/CDCHealthcareWorkerStaffingPathwayCOVID-19 Healthcare Worker Staffing Pathwaydraft2020-04hl7
hl7.fhir.uv.cqmR4Measure/PreventiveCareandWellnessPatientLevelLinearCompositePreventive Care and Wellness Patient-level Linear Compositeactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/PreventiveCareandWellnessWeightedCompositePreventive Care and Wellness Weighted Compositeactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/PreventiveCareandWellnessAllOrNothingCompositePreventive Care and Wellness All-Or-Nothing Compositeactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/PreventiveCareandWellnessOpportunityCompositePreventive Care and Wellness Opportunity Compositeactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/EXM55-FHIREXM55 - Median Emergency Department Visit Durationactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/Terminology-FHIRTerminology FHIRactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/BCSComponentBreast Cancer Screeningactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/HBPComponentPreventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documentedactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/PVSComponentPneumococcal Vaccination Status for Older Adultsactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/TSCComponentPreventive Care and Screening: Tobacco Use: Screening and Cessation Interventionactive2025-08hl7
hl7.fhir.uv.cqmR4Measure/CCSComponentCervical Cancer Screeningactive2025-08hl7
example.fhir.uv.mycontentigR4Measure/HybridHospitalWideMortalityFHIRExampleCore Clinical Data Elements for the Hybrid Hospital-Wide (All-Condition, All-Procedure) Risk-Standardized Mortality Measure (HWM) FHIR Exampledraft2025-08hl7
hl7.fhir.uv.cqmR4Measure/EXM108-FHIREXM108 - Venous Thromboembolism Prophylaxisactive2025-08hl7
hl7.fhir.uv.sanerR4Measure/PatientsByRiskFactorWithSupplementalDataCOVID-19 Patients By Risk Factordraft2024-05hl7
hl7.fhir.uv.sanerR4Measure/ComputableCDCPatientImpactAndHospitalCapacityPatient Impact and Hospital Capacitydraft2024-05hl7
hl7.fhir.uv.sanerR4Measure/FEMADailyHospitalCOVID19ReportingFEMA Laboratory Orders and Results Daily Increase Reportingdraft2024-05hl7
hl7.fhir.uv.sanerR4Measure/CDCPatientImpactAndHospitalCapacityPatient Impact and Hospital Capacitydraft2024-05hl7
hl7.fhir.uv.cqmR4Measure/MultiRateExample-FHIRMulti-Rate Example Measureactive2025-08hl7
hl7.fhir.uv.cpgR4Measure/chf-urine-out-measureCHF Urine Out Metricactive2024-11hl7